Halozyme Therapeutics (HALO) Intangibles (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Intangibles data on file, last reported at $952.0 million in Q1 2026.

• Intangibles for Q1 2026 came in at $952.0 million, up 147.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $952.0 million (up 147.86% YoY), and the FY2025 annual result was $981.5 million, up 144.25% from the prior year.
• Intangibles retreated to $952.0 million in Q1 2026 per HALO's latest filing, from $981.5 million in the prior quarter.
• Over five years, Intangibles peaked at $981.5 million in Q4 2025 and troughed at $348.5 million in Q3 2025.
• A 5-year average of $576.3 million and a median of $481.8 million in 2023 frame the typical range for Intangibles.
• The sharpest annual moves came in 2023 and 2026: Intangibles plunged 48.29% in 2023, then jumped 147.86% in 2026.
• A 5-year view of Intangibles shows it stood at $546.7 million in 2022, then fell by 13.5% to $472.9 million in 2023, then decreased by 15.02% to $401.8 million in 2024, then soared by 144.25% to $981.5 million in 2025, then slipped by 3.01% to $952.0 million in 2026.
• Business Quant data shows HALO's Intangibles at $952.0 million in Q1 2026, $981.5 million in Q4 2025, and $348.5 million in Q3 2025.